Results 191 to 200 of about 184,779 (275)

Influence of self-care using complementary and integrative therapies during the COVID-19 pandemic in children and adolescents aged 4 to 13 years with bruxism and temporomandibular disorders

open access: diamond, 2022
Ana Cristina Soares Caruso França Biagini   +4 more
openalex   +2 more sources

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

open access: yesMolecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller   +17 more
wiley   +1 more source

Bridging Gaps in Migraine Management: A Comprehensive Review of Conventional Treatments, Natural Supplements, Complementary Therapies, and Lifestyle Modifications. [PDF]

open access: yesPharmaceuticals (Basel)
Abo-Elghiet F   +7 more
europepmc   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

open access: yesMolecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone   +11 more
wiley   +1 more source

Knowledge and use of complementary therapies in a tertiary care hospital in France: A preliminary study. [PDF]

open access: yesMedicine (Baltimore), 2020
Michel-Cherqui M   +6 more
europepmc   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

open access: yesMolecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy